This meta-analysis extends the evidence of Hirsche 1988 [32] that zidovudine treatment may increase the platelet levels in HIV patient, but does not support the relevance of the study conducted by Talargia et al. [33] that HIV patients with low CD4+ T count and zidovudine in their HARRT treatment regimen may have high risk of thrombocytopenia, because our study concludes that CD + T < 200 cells/μL may be associated with thrombocytopenia, so it is difficult to say that a zidovudine-including HAART regimen is the only predisposing factor for thrombocytopenia in HIV patients. This evidence concerns the gene CD4 and Thrombocytopenia.